Why the study?
Intramuscular FMD vaccines with oil-based adjuvants can induce muscle granulomas in pigs, making it important to establish a vaccine and delivery tool offering better immunity and safer application.
Does needleless intradermal vaccination prevent foot-and-mouth disease and reduce granuloma formation compared to intramuscular vaccination in pigs?
Does needleless intradermal vaccination prevent foot-and-mouth disease and reduce granuloma formation compared to intramuscular vaccination in pigs?
Needleless intradermal vaccination for foot-and-mouth disease provides effective protection while avoiding muscle granuloma formation in pigs.
Needleless intradermal FMD vaccination may avoid granulomas while maintaining protection in pigs; leaves open field efficacy and formulation optimization.
Vaccination is one of the most effective ways of controlling and preventing foot-and-mouth disease (FMD) outbreaks. The effective prevention of this disease requires the use of high-quality vaccines to meet the criteria that enable customers to use them simply. The administration of FMD vaccines containing oil-based adjuvants in pigs can induce the formation of granuloma in the muscle of the vaccinated, which makes these vaccines a less preferable option. Therefore, it is important to establish an FMD vaccine and vaccine delivery tool that offers better immunity and safer application. This study compared the immune responses of intramuscular and needleless intradermal vaccination in pigs. When the same amount of an FMD virus (FMDV) antigen was administered to pigs, both the intradermally and intramuscularly vaccinated groups were protected completely against a challenge of the homologous FMDV, but the intramuscularly vaccinated group showed an overall higher level of neutralizing antibodies. Importantly, the formation of granuloma in muscle could be excluded in the intradermally vaccinated group. Of the oil-based adjuvants selected in this study, ISA 207 was effective in eliciting immunogenicity in intradermal vaccination. In conclusion, a new vaccine formula can be chosen for the delivery of intradermal route to exclude the possibility of local reactions in the muscle and generate protective immunity against an FMDV challenge.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: